Immutep Ltd. IMMP 深 沪
等待开盘 12-20 09:30:00 美东时间
2.63
+0.010
+0.38%
华盛通- 最 高2.635
- 今 开2.56
- 成交量 12.23万股
- 最 低 2.5196
- 昨 收 2.62
- 总市值 3.87亿
- 52周最高 3.5299
- 市盈率 静 --
- 换手率 0.08%
- 52周最低 1.32
- 委 比 -87.90%
- 总股本 1.47亿
- 历史最高 7.95
- 量 比 0.60
- 振 幅 4.40%
- 历史最低 0.53
- 每 手 1
- 风险率 0.21%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Immutep Reports Operational Progress In TACTI-004 Phase III Trial Evaluating Eftilagimod Alfa In Combination With MSD's Anti-PD-1 Therapy, KEYTRUDA, And Chemotherapy As First Line Therapy For Advanced/Metastatic Non-Small Cell Lung Cancer
The registrational TACTI-004 Phase III has enrolled 289 patients globally, over 38% of the trial's targeted enrolmentStrong operational progress continues globally with over 120 activated clinical sites and 27 countries
12-16 21:02
美股牛股 | “减肥神药”临床数据引爆！WaVe生命科学涨超147%，硕迪生物涨超102%；Confluent涨超29%
“减肥神药”临床数据引爆！WaVe生命科学涨超147%，硕迪生物涨超102%；Confluent涨超29%，IBM拟110亿美元收购该公司>>
12-09 17:40
Immutep to Present New Data from AIPAC-003 Phase II at the 2025 San Antonio Breast Cancer Symposium
Immutep的AIPAC-003试验数据显示，eftilagimod alfa（efti）联合paclitaxel在治疗HR+和HER2阴性/低转移性乳腺癌患者中表现出显著的客观缓解率（ORR）和疾病控制率（DCR）。30mg剂量组达到41.9%的ORR和87.1%的DCR，90mg剂量组分别为48.5%和78.8%。此外，两个剂量均显示免疫激活生物标志物的显著增加。基于FDA的Project Optimus要求，30mg剂量被确定为最佳生物剂量（OBD）。90mg剂量耐受性较差，包括剂量限制毒性（DLT）和注射部位反应。这些结果将支持efti在非小细胞肺癌及其他癌症中的进一步开发。
12-02 13:00
Immutep Data From EFTISARC-NEO Study Evaluating Eftilagimod Alfa With Radiotherapy Plus KEYTRUDA Exceeds Prespecified Level Of Pathologic Response Rates, Reaches Median 51.5% Tumor Hyalinization/Fibrosis
Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep" or "the Company"), a late-stage immunotherapy company targeting cancer and autoimmune diseases, today announces positive data from the EFTISARC-NEO trial that were
11-13 21:02
Immutep Secures A$4.6 Million R&D Tax Incentive from French Government
Immutep Ltd ( ($AU:IMM) ) has issued an update. Immutep Limited has received a ...
11-03 08:08
Two Posters at ESMO Congress 2025 Highlight Immutep’s Focus on Changing Treatment Landscape in First Line Non-Small Cell Lung Cancer
<b>Immutep Announces Promising Results for Efti Combination in NSCLC</b> <br>Immutep's INSIGHT-003 trial shows that combining eftilagimod alfa (efti) with KEYTRUDA and chemotherapy achieved strong response rates (ORR) across all PD-L1 expression levels in first-line non-small cell lung cancer (1L NSCLC). Notably, the ORR was 61.7% in patients with low or no PD-L1 expression (TPS <50%), significantly outperforming historical controls (40.8%). The ...
10-20 12:00
Immutep’s Efti Shows Promising Results in Lung Cancer Treatment
Immutep Ltd ( ($AU:IMM) ) has provided an announcement. Immutep Limited has ann...
10-20 05:37
Immutep Announces Successful Completion of FDA Project Optimus Requirements
Immutep Limited has received positive feedback from the FDA confirming 30mg of eftilagimod alfa (efti) as the optimal biological dose for its oncology pipeline and future Biological License Applications (BLA). The registrational TACTI-004 (KEYNOTE-F91) Phase III trial for first-line non-small cell lung cancer (NSCLC) is now opening clinical sites in the United States. This trial evaluates efti combined with MSD’s KEYTRUDA and chemotherapy for adv...
10-13 12:00
Immutep Completes FDA Project Optimus, Advances Cancer Immunotherapy
An announcement from Immutep Ltd ( ($AU:IMM) ) is now available. Immutep Limite...
10-13 06:18
Immutep Announces Its Global Phase III TACTI-004 Trial For Advanced Non-Small Cell Lung Cancer Has Surpassed Key Milestone With Over 170 Patients Enrolled And Randomized
Global Phase III trial has enrolled and randomised over 170 patients, reaching an important milestone as this is above the amount needed to conduct the futility analysisOver 100 clinical sites across 24 countries now
10-09 20:07
